GlobeNewswire Inc | Dec 22, 2021 04:05PM EST

December 22, 2021

NESS ZIONA, Israel, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will participate in the LifeSci Partners 11th Annual Corporate Access Event and the H.C. Wainwright BioConnect Conference, both of which will be held virtually.

Event details are as follows:

LifeSci Partners 11^th Annual Corporate Access EventFormat 1-on-1 meetingsDate: January 5, 2022Registration Link H.C. Wainwright BioConnect 2022 Healthcare ConferenceFormat Webcast of corporate presentationDate: Webcast on demand starting at 7:00 am ET January 10 through January 13, 2022Registration Link

AboutSol-Gel Technologies

Sol-Gelis a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. SolGel leverages its proprietary microencapsulation technology platform for TWYNEO, which is FDA approved for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older; and EPSOLAY, under investigation for the treatment of inflammatory lesions of rosacea with an NDA filed with the FDA and a PDUFA goal date that was set forApril26,2021. Action on the NDA for EPSOLAY has not yet been taken due to the inability of the FDA to conduct a preapproval inspection of the production site of EPSOLAY as a result of COVID19 travel restrictions. On December 21, 2021, Sol-Gel announced that FDA has updated Sol-Gel the pre-approval inspection for EPSOLAY will occur the week of February 14, 2022. Both product candidates are exclusively licensed forU.S.commercialization withGalderma. The Companys pipeline also includes early-stage topical drug candidates SGT-210 (erlotinib gel) under investigation for the treatment ofpalmoplantar keratoderma, SGT-310 (tapinarof cream, 1%) and SGT-510 (roflumilast) under investigation for the treatment ofplaque psoriasis and other dermatologic indications. For additional information, please visitwww.sol-gel.com.

Contact:

Irina KofflerInvestor relations,LifeSci Advisorsikoffler@lifesciadvisors.com+1 917 734 7387

Sol-Gel TechnologiesGilad MamlokChief Financial Officergilad.mamlok@sol-gel.com